Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: hypertrophic cardiomyopathy (HCM)

hypertrophied human heart
June 3, 2024/Heart, Vascular and Thoracic/Cardiac Surgery

A Transaortic Approach to Midventricular and Apical Septal Myectomy

Large single-center series demonstrates safety and efficacy for extending procedure

CQD-4040874-vigorousexercise-650×450
January 22, 2024/Pediatrics/Cardiology

Is Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy Less Risky Than Previously Thought?

JAMA study adds new data to decades-long guidance

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023/Genomic Medicine

Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

23-HVI-4172009 CQD 650×450-2
August 29, 2023/Heart, Vascular and Thoracic/Research

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-HVI-3509429_obstructive-hypertrophic-cardiomyopathy_650x450
January 27, 2023/Heart, Vascular and Thoracic/Clinical Cardiology

Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning

An abundance of promising studies are on the horizon

22-HVI-3393756_echo-showing-obstructive-HCM_ 650×450
December 2, 2022/Heart, Vascular and Thoracic/Imaging

VALOR-HCM Substudy: Mavacamten Improves Left Ventricular Diastolic Function

Gains are associated with clinical and biomarker benefits in obstructive HCM

22-HVI-3276959_obstructive-HCM-strain-imaging_650x450
November 7, 2022/Heart, Vascular and Thoracic/Clinical Cardiology

Mavacamten’s Effects Against Obstructive Hypertrophic Cardiomyopathy Persist Through 32 Weeks in VALOR-HCM

Latest results confirm and build on 16-week findings

21-HVI-2577809_septal-myectomy-LVOTO-repair_650x450
January 6, 2022/Heart, Vascular and Thoracic/Research

Study Confirms Quality-of-Life Benefits of Myectomy in Obstructive HCM

Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up

21-HVI-2500367-hypertrophic-cardiomyopathy-650×450
November 18, 2021/Heart, Vascular and Thoracic/Clinical Cardiology

In Obstructive Hypertrophic Cardiomyopathy, One Size Does Not Fit All

Why we favor a tailored approach to relieve LVOT obstruction

21-CHP-2303160-Hero-650×450
September 2, 2021/Pediatrics/Cardiology

Pediatric Waitlist and Heart Transplant Mortality Rates Similar in All Cardiomyopathy Phenotypes

VADs remain underutilized in non-dilated cardiomyopathy patients

BackPage 1 of 2Next

Advertisement

Ad